Get the Daily Brief
Latest Biotech News
Metabolism drives fungal invasion: CCMB identifies therapeutic levers
Researchers at the Centre for Cellular and Molecular Biology (CCMB) reported that metabolic pathways underlie fungal invasion and influence responses to antifungal therapy. The team identified...
Triple blockade ignites CXCL16–CXCR6 tumor immunity – STING, TGF‑β, PD‑L1 targeted
A research team reported that simultaneous modulation of STING, TGF‑β, and PD‑L1 pathways markedly enhanced antitumor responses via the CXCL16–CXCR6 signaling axis. The triple‑targeting approach...
Inflammasome protein ASC rewires pancreatic cancer metabolism – Nature Communications
A Nature Communications study led by Chey, Kashgari, and McLeod identified the inflammasome‑associated protein ASC as a central regulator connecting innate immune signaling to mitochondrial...
3D gut‑brain‑vascular model maps bidirectional disease mechanisms
Researchers published a Nature Communications report introducing a 3D gut‑brain‑vascular platform that models communication among the gut, brain, and vasculature. The system reproduces key...
Brepocitinib proof-of-concept clears cutaneous sarcoidosis – Roivant advances to pivotal
Roivant subsidiary Priovant reported that brepocitinib, a dual JAK1/TYK2 inhibitor licensed from Pfizer, met the primary goals of a proof-of-concept study in cutaneous sarcoidosis. The trial...
Sanofi data drop: tolebrutinib misses primary in PPMS – program retreats
Sanofi disclosed data from a failed Phase 3 trial of the BTK inhibitor tolebrutinib in primary progressive multiple sclerosis (PPMS), prompting the company to retreat from that indication. The...
Phage plus antibiotic defeats MDR Klebsiella peritonitis – new combo therapy shown
Researchers published a Nature Communications study showing a bacteriophage–antibiotic combination cured refractory peritoneal dialysis–related peritonitis caused by multidrug-resistant Klebsiella...
ASC inflammasome links immune sensing to metabolism in pancreatic cancer
A Nature Communications paper by Chey, Kashgari, McLeod and colleagues identified the inflammasome-associated protein ASC as a central regulator connecting innate immune signaling to mitochondrial...
STING–TGF‑β–PD‑L1 triple targeting magnifies CXCL16–CXCR6 tumor response
Researchers reported that simultaneously modulating STING, TGF‑β, and PD‑L1 pathways dramatically enhances antitumor immunity through activation of the CXCL16–CXCR6 axis. The triple-targeting...
LRRK2 R1627P intensifies gut inflammation and α‑synuclein in models
A translational study showed that the Parkinson’s-linked LRRK2 R1627P mutation amplifies gut inflammation and promotes α‑synuclein aggregation in rat models. Investigators reported increases in...
CCMB finds fungal metabolic switches that enable invasion and alter antifungal response
Scientists at the Centre for Cellular and Molecular Biology (CCMB) reported that metabolic programs in fungi underpin invasive behavior and determine responsiveness to antifungal therapy. The team...
Las Vegas raid: Israeli-linked biolab leaves residents 'deathly ill' — FBI seizes samples
Las Vegas police and federal agents arrested an Israeli national, Ori Salomon (aka Ori Solomon), after a residential property used as an alleged biological laboratory reportedly left several...
Hims halts compounded GLP‑1 sales after federal and industry legal pressure
Telehealth company Hims & Hers announced it would stop offering a compounded version of Novo Nordisk’s Wegovy following legal threats from federal regulators and pressure from Novo Nordisk. The...
OpenEvidence hits $12B valuation — doctors driving adoption, pharma ads follow
OpenEvidence reached a $12 billion valuation as investor demand climbed behind its clinician‑first AI medical search tool, which the company says is used regularly by more than 430,000 clinicians....
Hims halts GLP‑1 sales — FDA legal threat forces U‑turn
Hims & Hers abruptly stopped offering a compounded version of Novo Nordisk’s Wegovy after escalating legal pressure from U.S. federal regulators and threats of enforcement action. The company...
Roivant’s brepocitinib clears proof‑of‑concept — pivotal test next
A Priovant Therapeutics proof‑of‑concept study showed brepocitinib, a dual JAK1/TYK2 inhibitor licensed from Pfizer, met its goals in cutaneous sarcoidosis — a rare inflammatory skin disorder with...
Las Vegas raid seizes makeshift biolab — Israeli national arrested, samples sent to FBI
Las Vegas police arrested an Israeli national after discovering a residential property configured as an apparent biological laboratory with freezers, a biosafety hood, centrifuge and more than...
OpenEvidence valuation hits $12B: 430,000 clinicians using free AI search
OpenEvidence’s reported $12 billion valuation reflects rapid clinical adoption of its doctor‑first AI medical search tool, which the company says is used regularly by more than 430,000 clinicians...
Phage plus antibiotic halts resistant peritonitis — synergy shown in Nature Communications
Researchers publishing in Nature Communications reported that a bacteriophage‑antibiotic combination successfully cleared refractory peritoneal dialysis‑related peritonitis caused by Klebsiella...
Inflammasome protein ASC rewires pancreatic cancer metabolism — Nature Communications
A 2026 Nature Communications paper identified the inflammasome‑associated protein ASC as a molecular link between innate immune signaling and mitochondrial metabolism in pancreatic cancer cells....